Naloxone formulations for sublingual and/or buccal administration
US12303597B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 31, 2023 |
| Grant date | May 20, 2025 |
| Priority date | — |
| Expiry date | Aug 31, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Liquid, gel, and semi-solid compositions containing naloxone base, or isomers or derivatives thereof, with one or more non-aqueous solvents, and optional viscosity adjusting agents, are provided. Methods of treating an individual exhibiting symptoms of respiratory depression associated with known or suspected opioid overdose including administering a liquid, gel, or semi-solid formulation containing a solution of naloxone base, or an isomer or a derivative thereof, in one or more non-aqueous solvents, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.